Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Renner

Showing results (111-120 of 121) with videos related to

Pageof 13
Sort By:
Cancers|May 14, 2022
Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA)Markus Joerger, Yannis Metaxas, Khalil Zaman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2018
Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized MicePratiksha Gulati, Julia Rühl, Abhilash Kannan, et al.
Eclinicalmedicine|October 2, 2023
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)Urban Novak, Martin Fehr, Sämi Schär, et al.
The Journal of Experimental Medicine|April 20, 2005
Structural and kinetic basis for heightened immunogenicity of T cell vaccinesJi-Li Chen, Guillaume Stewart-Jones, Giovanna Bossi, et al.
Rheumatology (Oxford, England)|June 28, 2013
The arthritis-associated HLA-B*27:05 allele forms more cell surface B27 dimer and free heavy chain ligands for KIR3DL2 than HLA-B*27:09Alberto Cauli, Jacqueline Shaw, Joanna Giles, et al.
Hematological Oncology|December 7, 2023
Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021Jakob R Passweg, Helen Baldomero, Marc Ansari, et al.
Haematologica|July 11, 2015
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myelomaJesus F San Miguel, Katja C Weisel, Kevin W Song, et al.
Haematologica|August 8, 2015
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasoneMeletios A Dimopoulos, Katja C Weisel, Kevin W Song, et al.
Swiss Medical Weekly|March 2, 2018
Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016Jakob R Passweg, Helen Baldomero, Marc Ansari, et al.
Hemasphere|May 22, 2025
Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalitionAnna Ossami Saidy, Christophe Peczynski, Catherine Thieblemont, et al.
Pageof 13

Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
Cancers|May 14, 2022
Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA)Markus Joerger, Yannis Metaxas, Khalil Zaman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2018
Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized MicePratiksha Gulati, Julia Rühl, Abhilash Kannan, et al.
Eclinicalmedicine|October 2, 2023
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)Urban Novak, Martin Fehr, Sämi Schär, et al.
The Journal of Experimental Medicine|April 20, 2005
Structural and kinetic basis for heightened immunogenicity of T cell vaccinesJi-Li Chen, Guillaume Stewart-Jones, Giovanna Bossi, et al.
Rheumatology (Oxford, England)|June 28, 2013
The arthritis-associated HLA-B*27:05 allele forms more cell surface B27 dimer and free heavy chain ligands for KIR3DL2 than HLA-B*27:09Alberto Cauli, Jacqueline Shaw, Joanna Giles, et al.
Hematological Oncology|December 7, 2023
Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021Jakob R Passweg, Helen Baldomero, Marc Ansari, et al.
Haematologica|July 11, 2015
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myelomaJesus F San Miguel, Katja C Weisel, Kevin W Song, et al.
Haematologica|August 8, 2015
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasoneMeletios A Dimopoulos, Katja C Weisel, Kevin W Song, et al.
Swiss Medical Weekly|March 2, 2018
Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016Jakob R Passweg, Helen Baldomero, Marc Ansari, et al.
Hemasphere|May 22, 2025
Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalitionAnna Ossami Saidy, Christophe Peczynski, Catherine Thieblemont, et al.
Pageof 13